Dr. Ioanna Kosmidou, MD

Dr. Kosmidou practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Kosmidou's NPI, 1801067376, was assigned on March 12, 2008. Dr. Kosmidou graduated from University of Patras School of Medicine in 1998. Dr. Kosmidou holds New York license 277824.

Dr. Kosmidou's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Kosmidou's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. Dr. Kosmidou is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is Memorial Cardiopulmonary Group. Dmand AI also links Dr. Kosmidou to 1 more hospital, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kosmidou practices, 5 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Kosmidou's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Kosmidou is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Kosmidou's licenses on file in 4 states: New York, Florida, New Jersey and Georgia.

Dmand AI lists chronic hypertension, coronary artery disease and high cholesterol among the conditions Dr. Kosmidou treats.

CMS data shows 5,890 Medicare services from Dr. Kosmidou across 8 procedure codes in 2024, for 4,084 Medicare patients. Medicare paid $68,118 for them.

CMS counts 4,084 Medicare patients who saw Dr. Kosmidou in 2024. The largest group is 65 to 74, with 1,904 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.38, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kosmidou's median patient age at 69, with 50% women.

In 2024, Dr. Kosmidou wrote 494 Medicare Part D claims for 91 patients. 76% of them were for generic drugs. CMS names the drug for 396 of them, across 15 drugs with 11 or more claims each, at $119,352 in total drug cost. In 2023, CMS named 242 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Kosmidou for performance year 2024, reported as part of a group. Dr. Kosmidou accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kosmidou as offering telehealth.

Dmand AI links 68 papers to Dr. Kosmidou, published from 2006 to 2025. 2019 was the busiest year, with 7. The most frequent topics are Percutaneous Coronary Intervention, Atrial Fibrillation and Coronary Artery Disease. Dr. Kosmidou has published most often in Am J Cardiol. Dr. Kosmidou's most frequent co-authors are Ori Ben-Yehuda, MD, Roxana Mehran, MD and Martin Bert Leon, MD.

CMS Open Payments shows 70 general payments to Dr. Kosmidou from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. Abbott Laboratories paid the most, $24,237.

Dmand AI lists 3 awards for Dr. Kosmidou, most recently CMS Stage 1 EHR in 2013.

Dr. Kosmidou graduated from University of Patras School of Medicine in 1998. Dr. Kosmidou is a member of HRS.

Dr. Kosmidou is in network with 11 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.